Page 19 - GPD-3-4

Gene & Protein in Disease Human sirtuins (SIRT1-7) in cancer

doi: 10.1155/2021/1173869 70. Yan SM, Han X, Han PJ, Chen HM, Huang LY, Li Y. SIRT3 is
a novel prognostic biomarker for esophageal squamous cell
60. Du Y, Wu J, Zhang H, Li S, Sun H. Reduced expression
of SIRT2 in serous ovarian carcinoma promotes cell carcinoma. Med Oncol. 2014;31(8):103.
proliferation through disinhibition of CDK4 expression. doi: 10.1007/s12032-014-0103-8
Mol Med Rep. 2017;15(4);1638-1646.
71. Elkady N, Aldesoky AI, Dawoud MM. Evaluation of ARK5
doi: 10.3892/mmr.2017.6183 and SIRT3 expression in renal cell carcinoma and their
clinical significance. Diagn Pathol. 2023;18(1):125.
61. Wilking-Busch MJ, Ndiaye MA, Huang W, Ahmad N.
Expression profile of SIRT2 in human melanoma and doi: 10.1186/s13000-023-01409-6
implications for sirtuin-based chemotherapy. Cell Cycle. 72. Torrens-Mas M, Oliver J, Roca P, Sastre-Serra J. SIRT3: Oncogene
2017;16(6):574-577.
and tumor suppressor in cancer. Cancers (Basel). 2017;9:90.
doi: 10.1080/15384101.2017.1288323
doi: 10.3390/cancers9070090
62. Deng A, Ning Q, Zhou L, Liang Y. SIRT2 is an unfavorable 73. Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic
prognostic biomarker in patients with acute myeloid target with oncogenic and tumor-suppressive function in
leukemia. Sci Rep. 2016;6:27694.
cancer. Cell Death Dis. 2014;5:e1047.
doi: 10.1038/srep27694
doi: 10.1038/cddis.2014.14
63. Schmidt AV, Monga SP, Prochownik EV, Goetzman ES. 74. Xu L, Li Y, Zhou L, et al. SIRT3 elicited an anti-
A novel transgenic mouse model implicates Sirt2 as a
promoter of hepatocellular carcinoma. Int J Mol Sci. Warburg effect through HIF1α/PDK1/PDHA1 to
2023;24(16):12618. inhibit cholangiocarcinoma tumorigenesis. Cancer Med.
2019;8:2380-2391.
doi: 10.3390/ijms241612618
doi: 10.1002/cam4.2089
64. Zhang L, Kim S, Ren X. The clinical significance of SIRT2 75. Zou X, Zhu Y, Park SH, et al. SIRT3-mediated dimerization
in malignancies: A tumor suppressor or an oncogene? Front of IDH2 directs cancer cell metabolism and tumor growth.
Oncol. 2020;10:1721.
Cancer Res. 2017;77:3990-3999.
doi: 10.3389/fonc.2020.01721
doi: 10.1158/0008-5472.CAN-16-2393
65. Chen J, Chan AW, To KF, et al. SIRT2 overexpression
in hepatocellular carcinoma mediates epithelial to 76. Paku M, Haraguchi N, Takeda M, et al. SIRT3-mediated
mesenchymal transition by protein kinase B/glycogen SOD2 and PGC-1α contribute to chemoresistance in
synthase kinase-3β/β-catenin signaling. Hepatology. colorectal cancer cells. Ann Surg Oncol. 2021;28:4720-4732.
2013;57(6):2287-2298. doi: 10.1245/s10434-020-09373-x
doi: 10.1002/hep.26278 77. Chen J, Wang A, Chen Q. SirT3 and p53 deacetylation in
aging and cancer. J Cell Physiol. 2017;232:2308-2311.
66. Cui Y, Qin L, Wu J, et al. SIRT3 enhances glycolysis and
proliferation in SIRT3-expressing gastric cancer cells. PLoS doi: 10.1002/jcp.25669
One. 2015;10(6):e0129834.
78. Luo K, Huang W, Tang S. Sirt3 enhances glioma cell viability
doi: 10.1371/journal.pone.0129834 by stabilizing Ku70-BAX interaction. Onco Targets Ther.
2018;11:7559-7567.
67. Wang Y, Sun X, Ji K, et al. Sirt3-mediated mitochondrial
fission regulates the colorectal cancer stress response by doi: 10.2147/OTT.S172672
modulating the Akt/PTEN signalling pathway. Biomed 79. Chen Z, Lin J, Feng S, et al. SIRT4 inhibits the proliferation,
Pharmacother. 2018;105:1172-1182. migration, and invasion abilities of thyroid cancer cells
doi: 10.1016/j.biopha.2018.06.071 by inhibiting glutamine metabolism. Onco Targets Ther.
2019;12:2397-2408.
68. Zu Y, Chen XF, Li Q, Zhang ST, Si LN. PGC-1α activates SIRT3
to modulate cell proliferation and glycolytic metabolism in doi: 10.2147/OTT.S189536
breast cancer. Neoplasma. 2021;68(2):352-361.
80. Fu L, Dong Q, He J, et al. SIRT4 inhibits malignancy
doi: 10.4149/neo_2020_200530N584 progression of NSCLCs, through mitochondrial
dynamics mediated by the ERK-Drp1 pathway. Oncogene.
69. George J, Nihal M, Singh CK, Zhong W, Liu X, Ahmad N. 2017;36(19):2724-2736.
Pro-proliferative function of mitochondrial sirtuin
deacetylase SIRT3 in human melanoma. J Invest Dermatol. doi: 10.1038/onc.2016.425
2016;136(4):809-818.
81. Yin J, Cai G, Wang H, Chen W, Liu S, Huang G. SIRT4 is
doi: 10.1016/j.jid.2015.12.026 an independent prognostic factor in bladder cancer and

Volume 3 Issue 4 (2024) 11 doi: 10.36922/gpd.4100